Home
SCLX
SCLX News

Latest Scilex Holding Company (SCLX) News on April 1, 2025

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

GlobeNewswire

6 days ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

GlobeNewswire

22 days ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Breakeven Is Near for Scilex Holding Company (NASDAQ:SCLX)

Simply Wall St.

a month ago

Breakeven Is Near for Scilex Holding Company (NASDAQ:SCLX)

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

GlobeNewswire

2 months ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

GlobeNewswire

2 months ago

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

GlobeNewswire

2 months ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

GlobeNewswire

2 months ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

GlobeNewswire

2 months ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

GlobeNewswire

2 months ago

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

Zacks Small Cap Research

2 months ago

SCLX Beats on Earnings as Product Line Expands

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

GlobeNewswire

2 months ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 01/17/2025

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

GlobeNewswire

3 months ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/16/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/15/2025

Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%

TipRanks

3 months ago

Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/14/2025

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

GlobeNewswire

3 months ago

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/13/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/09/2025

GlobeNewswire

3 months ago

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/08/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/07/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/06/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 01/03/2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/31/2024

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

GlobeNewswire

3 months ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/30/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/27/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/26/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/24/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/23/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/20/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/19/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/18/2024

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/17/2024

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

GlobeNewswire

4 months ago

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/16/2024

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

GlobeNewswire

4 months ago

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/13/2024

Scilex Holding Company Announces $17 Million Registered Direct Offering

GlobeNewswire

4 months ago

Scilex Holding Company Announces $17 Million Registered Direct Offering

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/12/2024

MT Newswires

4 months ago

Scilex Holding Venture Initiates Trial Enrollment for Alzheimer's Treatment

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

GlobeNewswire

4 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

GlobeNewswire

4 months ago

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/11/2024

Zacks Small Cap Research

4 months ago

SCLX Gets Exclusive Rights to Important Drug

NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases

GlobeNewswire

4 months ago

NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease

GlobeNewswire

4 months ago

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/10/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/09/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/06/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/05/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/04/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

MT Newswires

4 months ago

Scilex Gets Nasdaq's Noncompliance Notification

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/22/2024

Scilex Holding Company Announces Receipt of Notice from Nasdaq

GlobeNewswire

4 months ago

Scilex Holding Company Announces Receipt of Notice from Nasdaq

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/21/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/20/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/19/2024

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/18/2024

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

GlobeNewswire

5 months ago

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/15/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/14/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/13/2024

GlobeNewswire

5 months ago

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/08/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/07/2024

MT Newswires

5 months ago

Scilex Shares Rise After Denali Capital's Registration Statement for Semnur Deal

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

GlobeNewswire

5 months ago

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/06/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/05/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/04/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 11/01/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/31/2024

Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock

Simply Wall St.

5 months ago

Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/30/2024

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

GlobeNewswire

5 months ago

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/29/2024

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

GlobeNewswire

5 months ago

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/28/2024

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

GlobeNewswire

5 months ago

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/25/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/24/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/23/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/22/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/21/2024

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 10/21/2024

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 10/18/2024

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Premarket Wednesday

MT Newswires

6 months ago

Scilex Considers Spinning off Scilex Pharma Unit Among Other Options -- Shares Rise Pre-Bell

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

GlobeNewswire

6 months ago

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

Share on Social Networks: